ClinicalTrials.gg
CompletedNCT00063570Updated May 29, 2009Results posted

Pemetrexed Plus Gemcitabine in Metastatic Breast Cancer Patients After Receiving Taxane Therapy

A Phase 2 interventional study of Pemetrexed and Gemcitabine in Breast Cancer and Breast Neoplasms, sponsored by Eli Lilly and Company. Completed at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-05-29.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
73
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 14 studies testing pemetrexed in Breast Neoplasms — none open to participants now, none under way, none of them phase 3. Pemetrexed · Breast Neoplasms.

Enrollment
6th of 13
73 · median 50
Started
2003
with 2 others
Phase 2
10 of 14
none open now
Registered
1st of 14
by date
Lead sponsor
10 of 14
Eli Lilly and Company

Among the 14 studies testing pemetrexed in Breast Neoplasms, this one is the 6th largest by enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2003, is one of 10 in phase 2, and was the 1st registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

None of the 14 studies testing pemetrexed in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →

About pemetrexed

Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing pemetrexed in Breast Neoplasms as a file.
02

Study summary

The purpose of the study is to determine if the two drugs can help patients feel better while causing the tumor to become smaller or disappear; evaluate the safety of giving both pemetrexed and gemcitabine in patients with advanced breast cancer.

03

Conditions studied

  • Breast Cancer
  • Breast Neoplasms

Browse trials for

Keywords

  • Cancer of Breast
  • Cancer of the Breast
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have received prior chemotherapy with Taxol (paclitaxel) or Taxotere (docetaxel).
  • Less than 3 different chemotherapy treatments for disease.
  • Prior treatment with hormonal and/or radiation therapy.
  • Must have disease that can be measured.
  • Must be able to take care of self needs for example personal hygiene

Exclusion criteria

Exclusion Criteria:

  • Must not be pregnant or breast-feeding.
  • Cancer that has spread to the brain.
  • Treatment with Gemcitabine or Pemetrexed
  • Unable to take folic acid or Vitamin B12
  • Treatment for another cancer within the last 5 years
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
73 participants (actual)

Study arms

  • Experimental
    A

    Drug: Pemetrexed · Drug: Gemcitabine

  • Experimental
    B

    Drug: Gemcitabine · Drug: Pemetrexed

Interventions

  • 500 mg/m2, intravenous (IV), every 14 days, until disease progression

    Also known as: LY231514, Alimta

  • 1500 mg/m2, intravenous (IV), every 14 days, until disease progression

    Also known as: LY188011, Gemzar

  • 1000 mg/m2, intravenous (IV), on Days 1 and 8 of 21-day cycle, until disease progression

    Also known as: LY188011, Gemzar

  • 500 mg/m2, intravenous (IV), every 21 days, until disease progression

    Also known as: LY231514, Alimta

06

What researchers measure

Primary outcomes

  1. Overall Tumor Response

    Best overall (confirmed) response recorded from start of treatment until disease progression/recurrence, start of other anti-tumor therapy/intervention, or end of trial, whichever comes first. Response must be confirmed at least 6 weeks from previous scans. Best overall response assignment depends on both measurement and confirmation criteria.

    Time frame: Every 6 weeks from start of treatment until documented disease progression or for 6 months from last dose of study drug, whichever occurs first. After 6 months, clinical assessment every 12 weeks and radiologic test performed as clinically indicated

Secondary outcomes

  1. Duration of (Confirmed) Complete Response or Partial Response

    Duration of response is calculated as (Date of First Disease Progression or Death as a Result of any Cause whichever Comes First - Date of First Objective Status Assessment of Confirmed CR or PR + 1)/(365.25/12).

    Time frame: Every 6 weeks from start of treatment until documented disease progression or for 6 months from last dose of study drug, whichever occurs first. After 6 months, clinical assessment every 12 weeks and radiologic test performed as clinically indicated

  2. Time to Progressive Disease

    Time to progressive disease is calculated as (Date of First Disease Progression or Death Due to Disease under Study whichever Comes First - First Dose Date + 1)/(365.25/12).

    Time frame: Every 6 weeks from start of treatment until documented disease progression or for 6 months from last dose of study drug, whichever occurs first. After 6 months, clinical assessment every 12 weeks and radiologic test performed as clinically indicated

  3. Time to Treatment Failure

    Time to treatment failure is calculated as (Date of First Disease Progression, Death as a Result of any Cause, or Early Discontinuation of Treatment Due to Adverse Event or Physician Perception of Lack of Efficacy or Patient and Physician Perception of Lack of Efficacy, whichever Comes First - First Dose Date + 1)/ (365.25/12)

    Time frame: Every 6 weeks from start of treatment until documented disease progression or for 6 months from last dose of study drug, whichever occurs first. After 6 months, clinical assessment every 12 weeks and radiologic test performed as clinically indicated

  4. Overall Survival

    Overall survival time is calculated as (Date of Death as a Result of any Cause - First Dose Date + 1)/ (365.25/12).

    Time frame: Every 6 weeks from start of treatment until documented disease progression or for 6 months from last dose of study drug, whichever occurs first. After 6 months, clinical assessment every 12 weeks and radiologic test performed as clinically indicated

07

Results

Posted May 13, 2009

Participant flow

Participant flow — Overall Study
MilestoneBi-Weekly Schedule21-Day Schedule
Started5221
Completed5221
Not completed00

Outcome measures

PrimaryOverall Tumor Response

Best overall (confirmed) response recorded from start of treatment until disease progression/recurrence, start of other anti-tumor therapy/intervention, or end of trial, whichever comes first. Response must be confirmed at least 6 weeks from previous scans. Best overall response assignment depends on both measurement and confirmation criteria.

Time frame:
Every 6 weeks from start of treatment until documented disease progression or for 6 months from last dose of study drug, whichever occurs first. After 6 months, clinical assessment every 12 weeks and radiologic test performed as clinically indicated
Reported as:
Number · participants
Overall Tumor Response
participantsBi-Weekly Schedule21-Day Schedule
Complete Response20
Partial Response85
Stable Disease2610
Progressive Disease146
Unknown20
SecondaryDuration of (Confirmed) Complete Response or Partial Response

Duration of response is calculated as (Date of First Disease Progression or Death as a Result of any Cause whichever Comes First - Date of First Objective Status Assessment of Confirmed CR or PR + 1)/(365.25/12).

Time frame:
Every 6 weeks from start of treatment until documented disease progression or for 6 months from last dose of study drug, whichever occurs first. After 6 months, clinical assessment every 12 weeks and radiologic test performed as clinically indicated
Reported as:
Median · months
Duration of (Confirmed) Complete Response or Partial Response
monthsBi-Weekly Schedule21-Day Schedule
Duration of (Confirmed) Complete Response or Partial Response5.85 (2.79 to 16.79)4.17 (3.71 to 17.61)
SecondaryTime to Progressive Disease

Time to progressive disease is calculated as (Date of First Disease Progression or Death Due to Disease under Study whichever Comes First - First Dose Date + 1)/(365.25/12).

Time frame:
Every 6 weeks from start of treatment until documented disease progression or for 6 months from last dose of study drug, whichever occurs first. After 6 months, clinical assessment every 12 weeks and radiologic test performed as clinically indicated
Reported as:
Median · months
Time to Progressive Disease
monthsBi-Weekly Schedule21-Day Schedule
Time to Progressive Disease3.19 (0.16 to 18.20)4.01 (1.05 to 20.80)
SecondaryTime to Treatment Failure

Time to treatment failure is calculated as (Date of First Disease Progression, Death as a Result of any Cause, or Early Discontinuation of Treatment Due to Adverse Event or Physician Perception of Lack of Efficacy or Patient and Physician Perception of Lack of Efficacy, whichever Comes First - First Dose Date + 1)/ (365.25/12)

Time frame:
Every 6 weeks from start of treatment until documented disease progression or for 6 months from last dose of study drug, whichever occurs first. After 6 months, clinical assessment every 12 weeks and radiologic test performed as clinically indicated
Reported as:
Median · months
Time to Treatment Failure
monthsBi-Weekly Schedule21-Day Schedule
Time to Treatment Failure2.79 (0.16 to 18.20)2.56 (0.49 to 20.80)
SecondaryOverall Survival

Overall survival time is calculated as (Date of Death as a Result of any Cause - First Dose Date + 1)/ (365.25/12).

Time frame:
Every 6 weeks from start of treatment until documented disease progression or for 6 months from last dose of study drug, whichever occurs first. After 6 months, clinical assessment every 12 weeks and radiologic test performed as clinically indicated
Reported as:
Median · months
Overall Survival
monthsBi-Weekly Schedule21-Day Schedule
Overall Survival13.44 (0.76 to 36.60)16.20 (1.41 to 31.64)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bi-Weekly Schedule———
21-Day Schedule———
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventBi-Weekly Schedule21-Day Schedule
Febrile neutropeniaBlood and lymphatic system disorders4/521/21
ThrombocytopeniaBlood and lymphatic system disorders0/521/21
PyrexiaGeneral disorders2/521/21
Femur fractureInjury, poisoning and procedural complications0/521/21
DizzinessNervous system disorders0/521/21
DyspnoeaRespiratory, thoracic and mediastinal disorders0/521/21
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/521/21
Pulmonary oedemaRespiratory, thoracic and mediastinal disorders0/521/21
ErythemaSkin and subcutaneous tissue disorders0/521/21
Aortic stenosisVascular disorders0/521/21
Most frequent other events
Showing 10 of 100
Most frequent other events
EventBi-Weekly Schedule21-Day Schedule
NeutropeniaBlood and lymphatic system disorders23/5216/21
FatigueGeneral disorders35/5215/21
RashSkin and subcutaneous tissue disorders23/5215/21
NauseaGastrointestinal disorders28/5214/21
PyrexiaGeneral disorders15/5214/21
AnaemiaBlood and lymphatic system disorders23/5212/21
DiarrhoeaGastrointestinal disorders16/5212/21
HeadacheNervous system disorders11/5211/21
ConstipationGastrointestinal disorders26/526/21
Aspartate aminotransferase increasedInvestigations14/529/21

Baseline characteristics

Age Continuous
Age Continuous(years)Bi-Weekly Schedule21-Day ScheduleTotal
Median53.5 (33 to 73)50.7 (28 to 73)51.9 (28 to 73)
Sex: Female, Male
Sex: Female, Male(Participants)Bi-Weekly Schedule21-Day ScheduleTotal
Female522173
Male000
Region of Enrollment
Region of Enrollment(participants)Bi-Weekly Schedule21-Day ScheduleTotal
United States522173
Current Pathological Diagnosis
Current Pathological Diagnosis(paticipants)Bi-Weekly Schedule21-Day ScheduleTotal
Ductal breast carcinoma361248
Lobular breast carcinoma202
Adenocystic breast carcinoma011
Breast carcinoma448
Other7310
Unknown112
No current pathological diagnosis202
Karnofsky Performance Status (KPS)
Karnofsky Performance Status (KPS)(participants)Bi-Weekly Schedule21-Day ScheduleTotal
<=60 - Needs increasing assistance up to Death (0)000
70 - Unable to carry on normal activity415
80 - Activity with effort; some signs of disease11516
90 - Normal activity; minor signs of disease19928
100 - Normal no complaints; no evidence of disease17623
unknown101
Menopausal Status at Cycle 0
Menopausal Status at Cycle 0(participants)Bi-Weekly Schedule21-Day ScheduleTotal
Pre-Menopausal7310
Menopausal437
Post-Menopausal411556
Patients with Current Pathological Diagnosis
Patients with Current Pathological Diagnosis(participants)Bi-Weekly Schedule21-Day ScheduleTotal
Yes502171
No202
Race/Ethnicity
Race/Ethnicity(participants)Bi-Weekly Schedule21-Day ScheduleTotal
Caucasian442064
African415
East/Southeast Asian303
Hispanic101

1 further baseline measures are reported on the registry.

08

Study locations

7 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Aurora, Colorado, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Plantation, Florida, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Morrisville, North Carolina, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Philadelphia, Pennsylvania, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Dallas, Texas, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Seattle, Washington, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    San Juan, Puerto Rico
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2003, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.

Results were first posted in May 2009, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2003
First posted
Jul 1, 2003
Start
Jul 2003
Primary completionActual
Jan 2008
CompletionActual
Jan 2008
Results first posted
May 13, 2009
Last update
May 29, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00063570
First posted
Jul 1, 2003
Start date
Jul 2003
Primary completion
Jan 2008
Completion
Jan 2008
Results posted
May 13, 2009
Last update
May 29, 2009

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 317-615-4559 Mon-Fri from 9AM to 5PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pemetrexed · Gemcitabine

Start the discussion